Progressive Supranuclear Palsy and Corticobasal Degeneration.
4R tauopathies
Biomarkers
Clinical criteria
Corticobasal degeneration
Corticobasal syndrome
Epidemiology
Etiology
Neuropathology
Progressive supranuclear palsy
Treatment
Journal
Advances in experimental medicine and biology
ISSN: 0065-2598
Titre abrégé: Adv Exp Med Biol
Pays: United States
ID NLM: 0121103
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
12
1
2021
pubmed:
13
1
2021
medline:
16
2
2021
Statut:
ppublish
Résumé
Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are neurodegenerative tauopathies with neuronal and glial lesions composed of tau that is composed predominantly of isomers with four repeats in the microtubule-binding domain (4R tau). The brain regions vulnerable to pathology in PSP and CBD overlap, but there are differences, particularly with respect to distribution of neuronal loss, the relative abundance of neuronal and glial lesions, the morphologic features of glial lesions, and the frequency of comorbid pathology. Both PSP and CBD have a wide spectrum of clinical manifestations, including disorders of movement and cognition. Recognition of phenotypic diversity in PSP and CBD may improve antemortem diagnostic accuracy, which tends to be very good for the most common presentation of PSP (Richardson syndrome), but poor for the most characteristic presentation of CBD (corticobasal syndrome: CBS). Development of molecular and imaging biomarkers may improve antemortem diagnostic accuracy. Currently, multidisciplinary symptomatic and supportive treatment with pharmacological and non-pharmacological strategies remains the standard of care. In the future, experimental therapeutic trials will be important to slow disease progression.
Identifiants
pubmed: 33433875
doi: 10.1007/978-3-030-51140-1_11
doi:
Substances chimiques
tau Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
151-176Références
Josephs KA, Hodges JR, Snowden JS, Mackenzie IR, Neumann M, Mann DM et al (2011) Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol 122(2):137–153
pubmed: 21614463
pmcid: 3232515
doi: 10.1007/s00401-011-0839-6
Spillantini MG, Goedert M (2013) Tau pathology and neurodegeneration. Lancet Neurol 12(6):609–622
pubmed: 23684085
doi: 10.1016/S1474-4422(13)70090-5
Dickson DW (2004) Sporadic tauopathies: Pick’s disease, corticobasal degeneration, progressive suprnauclear palsy and argyrophilic grain disease. In: Esiri MM, Lee VMY, Trojanowski JQ (eds) The neuropathology of dementia, 2nd edn. Cambridge University Press, Cambridge/New York, pp 227–256
doi: 10.1017/CBO9780511526886.012
Falcon B, Zivanov J, Zhang W, Murzin AG, Garringer HJ, Vidal R et al (2019) Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules. Nature 568(7752):420–423
pubmed: 30894745
pmcid: 6472968
doi: 10.1038/s41586-019-1026-5
Fitzpatrick AWP, Falcon B, He S, Murzin AG, Murshudov G, Garringer HJ et al (2017) Cryo-EM structures of tau filaments from Alzheimer’s disease. Nature 547(7662):185–190
pubmed: 5552202
pmcid: 5552202
doi: 10.1038/nature23002
Kovacs GG, Ferrer I, Grinberg LT, Alafuzoff I, Attems J, Budka H et al (2016) Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathol 131(1):87–102
pubmed: 26659578
doi: 10.1007/s00401-015-1509-x
Togo T, Sahara N, Yen SH, Cookson N, Ishizawa T, Hutton M et al (2002) Argyrophilic grain disease is a sporadic 4-repeat tauopathy. J Neuropathol Exp Neurol 61(6):547–556
pubmed: 12071638
doi: 10.1093/jnen/61.6.547
Steele JC, Richardson JC, Olszewski J (1964) Progressive supranuclear palsy. A heterogenous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 10:333–359
pubmed: 14107684
doi: 10.1001/archneur.1964.00460160003001
Dickson DW, Hauw J-J, Agid Y, Litvan I (2011) Progressive supranuclear palsy and corticobasal degeneration. In: Dickson DW, Weller RO (eds) Neurodegeneration: the molecular pathology of dementia and movement disorders, 2nd edn. Wiley-Blackwell/International Society of Neuropathology, Chichester/West Sussex, p xvii, 477 p.
doi: 10.1002/9781444341256
Nath U, Ben-Shlomo Y, Thomson R, Morris HR, Wood N, Lees A et al (2001) The prevalence of progressive supranuclear palsy (Steele–Richardson–Olszewski syndrome) in the UK. Brain 124(7):1438–1449
pubmed: 11408338
doi: 10.1093/brain/124.7.1438
Coyle-Gilchrist IT, Dick KM, Patterson K, Rodríquez PV, Wehmann E, Wilcox A et al (2016) Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes. Neurology 86(18):1736–1743
pubmed: 27037234
pmcid: 4854589
doi: 10.1212/WNL.0000000000002638
Schrag A, Ben-Shlomo Y, Quinn N (1999) Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 354(9192):1771–1775
pubmed: 10577638
doi: 10.1016/S0140-6736(99)04137-9
Respondek G, Kurz C, Arzberger T, Compta Y, Englund E, Ferguson LW et al (2017) Which ante mortem clinical features predict progressive supranuclear palsy pathology? Mov Disord 32(7):995–1005
pubmed: 28500752
pmcid: 5543934
doi: 10.1002/mds.27034
Fleury V, Brindel P, Nicastro N, Burkhard PR (2018) Descriptive epidemiology of parkinsonism in the Canton of Geneva, Switzerland. Parkinsonism Relat Disord 54:30–39
pubmed: 29661694
doi: 10.1016/j.parkreldis.2018.03.030
Kawashima M, Miyake M, Kusumi M, Adachi Y, Nakashima K (2004) Prevalence of progressive supranuclear palsy in Yonago, Japan. Mov Disord: Off J Mov Disord Soc 19(10):1239–1240
doi: 10.1002/mds.20149
Takigawa H, Ikeuchi T, Aiba I, Morita M, Onodera O, Shimohata T et al (2016) Japanese longitudinal biomarker study in PSP and CBD (JALPAC): a prospective multicenter PSP/CBD cohort study in Japan. Parkinsonism Relat Disord 22:e120–e1e1
doi: 10.1016/j.parkreldis.2015.10.282
Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE et al (2017) Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord:n/a–n/a
Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC et al (1996) Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47(1):1–9
pubmed: 8710059
doi: 10.1212/WNL.47.1.1
Respondek G, Stamelou M, Kurz C, Ferguson LW, Rajput A, Chiu WZ et al (2014) The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord: Off J Mov Disord Soc 29(14):1758–1766
doi: 10.1002/mds.26054
Litvan I, Mangone CA, McKee A, Verny M, Parsa A, Jellinger K et al (1996) Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry 60(6):615–620
pubmed: 8648326
pmcid: 1073943
doi: 10.1136/jnnp.60.6.615
Maher E, Lees A (1986) The clinical features and natural history of the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 36(7):1005
pubmed: 3714047
doi: 10.1212/WNL.36.7.1005
Golbe LI, Davis PH, Schoenberg BS, Duvoisin RC (1988) Prevalence and natural history of progressive supranuclear palsy. Neurology 38(7):1031
pubmed: 3386818
doi: 10.1212/WNL.38.7.1031
Litvan I, Agid Y (1992) Progressive supranuclear palsy: clinical and research approaches. Oxford University Press, New York
Collins S, Ahlskog J, Parisi JE, Maraganore D (1995) Progressive supranuclear palsy: neuropathologically based diagnostic clinical criteria. J Neurol Neurosurg Psychiatry 58(2):167–173
pubmed: 7876846
pmcid: 1073312
doi: 10.1136/jnnp.58.2.167
Chamberlain W (1971) Restriction in upward gaze with advancing age. Am J Ophthalmol 71(1):341–346
pubmed: 5100473
doi: 10.1016/0002-9394(71)90409-0
Vidailhet M, Rivaud S, Gouider-Khouja N, Pillon B, Bonnet AM, Gaymard B et al (1994) Eye movements in parkinsonian syndromes. Ann Neurol: Off J Am Neurol Assoc Child Neurol Soc 35(4):420–426
doi: 10.1002/ana.410350408
Gibb W, Esiri M, Lees A (1987) Clinical and pathological features of diffuse cortical Lewy body disease (Lewy body dementia). Brain 110(5):1131–1153
pubmed: 2823957
doi: 10.1093/brain/110.5.1131
Grant MP, Cohen M, Petersen RB, Halmagyi GM, McDougall A, Tusa RJ et al (1993) Abnormal eye movements in Creutzfeldt–Jakob disease. Ann Neurol: Off J Am Neurol Assoc Child Neurol Soc 34(2):192–197
doi: 10.1002/ana.410340215
Paulson H, Subramony S (2003) Spinocerebellar Ataxia 3—Machado-Joseph disease (SCA3). In: Genetics of movement disorders. Elsevier, pp 57–69
Brüggemann N, Wandinger KP, Gaig C, Sprenger A, Junghanns K, Helmchen C et al (2016) Dystonia, lower limb stiffness, and upward gaze palsy in a patient with IgLON5 antibodies. Mov Disord 31(5):762–764
pubmed: 27030137
doi: 10.1002/mds.26608
Adams C, McKeon A, Silber MH, Kumar R (2011) Narcolepsy, REM sleep behavior disorder, and supranuclear gaze palsy associated with Ma1 and Ma2 antibodies and tonsillar carcinoma. Arch Neurol 68(4):521–524
pubmed: 21482933
doi: 10.1001/archneurol.2011.56
Boeve BF (2012) Progressive supranuclear palsy. Parkinsonism Relat Disord 18:S192–S1S4
pubmed: 22166432
doi: 10.1016/S1353-8020(11)70060-8
Garbutt S, Riley D, Kumar A, Han Y, Harwood M, Leigh R (2004) Abnormalities of optokinetic nystagmus in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 75(10):1386–1394
pubmed: 15377682
pmcid: 1738726
doi: 10.1136/jnnp.2003.027367
Quinn N (1996) The “round the houses” sign in progressive supranuclear palsy. Ann Neurol: Off J Am Neurol Assoc Child Neurol Soc 40(6):951
doi: 10.1002/ana.410400630
Lal V, Truong D (2019) Eye movement in movement disorders. Clin Parkinsonism Relat Disord 1:54–63
Kitthaweesin K, Riley DE, Leigh RJ (2002) Vergence disorders in progressive supranuclear palsy. Ann New York Acad Sci 956(1):504–507
doi: 10.1111/j.1749-6632.2002.tb02867.x
Yoon WT, Chung EJ, Lee SH, Kim BJ, Lee WY (2005) Clinical analysis of blepharospasm and apraxia of eyelid opening in patients with parkinsonism. J Clin Neurol 1(2):159–165
pubmed: 20396463
pmcid: 2854921
doi: 10.3988/jcn.2005.1.2.159
Williams DR, Watt HC, Lees AJ (2006) Predictors of falls and fractures in bradykinetic rigid syndromes: a retrospective study. J Neurol Neurosurg Psychiatry 77(4):468–473
pubmed: 16543524
pmcid: 2077491
doi: 10.1136/jnnp.2005.074070
Kluin KJ, Foster NL, Berent S, Gilman S (1993) Perceptual analysis of speech disorders in progressive supranuclear palsy. Neurology 43(3 Part 1):563
pubmed: 8451002
doi: 10.1212/WNL.43.3_Part_1.563
Müller J, Wenning GK, Verny M, McKee A, Chaudhuri KR, Jellinger K et al (2001) Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders. Arch Neurol 58(2):259–264
pubmed: 11176964
doi: 10.1001/archneur.58.2.259
Papapetropoulos S, Singer C, McCorquodale D, Gonzalez J, Mash DC (2005) Cause, seasonality of death and co-morbidities in progressive supranuclear palsy (PSP). Parkinsonism Relat Disord 11(7):459–463
pubmed: 16154793
doi: 10.1016/j.parkreldis.2005.06.003
Litvan I, Hauw J, Bartko J, Lantos P, Daniel S, Horoupian D et al (1996) Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol 55(1):97–105
pubmed: 8558176
doi: 10.1097/00005072-199601000-00010
Respondek G, Roeber S, Kretzschmar H, Troakes C, Al-Sarraj S, Gelpi E et al (2013) Accuracy of the National Institute for Neurological Disorders and Stroke/Society for Progressive Supranuclear Palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy. Mov Disord: Off J Mov Disord Soc 28(4):504–509
doi: 10.1002/mds.25327
Osaki Y, Ben-Shlomo Y, Lees AJ, Daniel SE, Colosimo C, Wenning G et al (2004) Accuracy of clinical diagnosis of progressive supranuclear palsy. Mov Disord 19(2):181–189
pubmed: 14978673
doi: 10.1002/mds.10680
Birdi S, Rajput AH, Fenton M, Donat JR, Rozdilsky B, Robinson C et al (2002) Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases. Mov Disord: Off J Mov Disord Soc 17(6):1255–1264
doi: 10.1002/mds.10211
Williams DR, de Silva R, Paviour DC, Pittman A, Watt HC, Kilford L et al (2005) Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson’s syndrome and PSP-parkinsonism. Brain 128(Pt 6):1247–1258
pubmed: 15788542
doi: 10.1093/brain/awh488
Williams DR, Holton JL, Strand K, Revesz T, Lees AJ (2007) Pure akinesia with gait freezing: a third clinical phenotype of progressive supranuclear palsy. Mov Disord: Off J Mov Disord Soc 22(15):2235–2241
doi: 10.1002/mds.21698
Boeve B, Dickson D, Duffy J, Bartleson J, Trenerry M, Petersen R (2003) Progressive nonfluent aphasia and subsequent aphasic dementia associated with atypical progressive supranuclear palsy pathology. Eur Neurol 49(2):72–78
pubmed: 12584413
doi: 10.1159/000068502
Boeve BF, Maraganore D, Parisi JE, Ahlskog J, Graff-Radford N, Caselli RJ et al (1999) Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology 53(4):795
pubmed: 10489043
doi: 10.1212/WNL.53.4.795
Josephs KA, Katsuse O, Beccano-Kelly DA, Lin W-L, Uitti RJ, Fujino Y et al (2006) Atypical progressive supranuclear palsy with corticospinal tract degeneration. J Neuropathol Exp Neurol 65(4):396–405
pubmed: 16691120
doi: 10.1097/01.jnen.0000218446.38158.61
Koga S, Josephs KA, Ogaki K, Labbé C, Uitti RJ, Graff-Radford N et al (2016) Cerebellar ataxia in progressive supranuclear palsy: an autopsy study of PSP-C. Mov Disord 31(5):653–662
pubmed: 26841329
pmcid: 4861661
doi: 10.1002/mds.26499
Josephs KA, Duffy JR (2008) Apraxia of speech and nonfluent aphasia: a new clinical marker for corticobasal degeneration and progressive supranuclear palsy. Curr Opin Neurol 21(6):688–692
pubmed: 18989114
doi: 10.1097/WCO.0b013e3283168ddd
Hassan A, Parisi JE, Josephs KA (2012) Autopsy-proven progressive supranuclear palsy presenting as behavioral variant frontotemporal dementia. Neurocase 18(6):478–488
pubmed: 22181323
doi: 10.1080/13554794.2011.627345
Han HJ, Kim H, Park JH, Shin HW, Kim GU, Kim DS et al (2010) Behavioral changes as the earliest clinical manifestation of progressive supranuclear palsy. J Clin Neurol (Seoul, Korea) 6(3):148–151
doi: 10.3988/jcn.2010.6.3.148
Ling H, O’Sullivan SS, Holton JL, Revesz T, Massey LA, Williams DR et al (2010) Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain 133(7):2045–2057
pubmed: 20584946
doi: 10.1093/brain/awq123
Ling H, De Silva R, Massey L, Courtney R, Hondhamuni G, Bajaj N et al (2014) Characteristics of progressive supranuclear palsy presenting with corticobasal syndrome: a cortical variant. Neuropathol Appl Neurobiol 40(2):149–163
pubmed: 23432126
pmcid: 4260147
doi: 10.1111/nan.12037
Nagao S, Yokota O, Nanba R, Takata H, Haraguchi T, Ishizu H et al (2012) Progressive supranuclear palsy presenting as primary lateral sclerosis but lacking parkinsonism, gaze palsy, aphasia, or dementia. J Neurol Sci 323(1–2):147–153
pubmed: 23026537
doi: 10.1016/j.jns.2012.09.005
Respondek G, Höglinger G (2016) The phenotypic spectrum of progressive supranuclear palsy. Parkinsonism Relat Disord 22:S34–SS6
pubmed: 26421392
doi: 10.1016/j.parkreldis.2015.09.041
Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ (2002) The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125(Pt 4):861–870
pubmed: 11912118
doi: 10.1093/brain/awf080
Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181–184
pubmed: 1564476
pmcid: 1014720
doi: 10.1136/jnnp.55.3.181
Williams DR, Holton JL, Strand C, Pittman A, de Silva R, Lees AJ et al (2007) Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson’s syndrome. Brain 130(6):1566–1576
pubmed: 17525140
doi: 10.1093/brain/awm104
Williams DR, Lees AJ (2010) What features improve the accuracy of the clinical diagnosis of progressive supranuclear palsy-parkinsonism (PSP-P)? Mov Disord 25(3):357–362
pubmed: 20108379
doi: 10.1002/mds.22977
Adler CH, Beach TG, Hentz JG, Shill HA, Caviness JN, Driver-Dunckley E et al (2014) Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study. Neurology 83(5):406–412
pubmed: 24975862
pmcid: 4132570
doi: 10.1212/WNL.0000000000000641
Richardson J, Steele J, Olszewski J (1963) Supranuclear opthalmoplegia, pseudobulbar palsy, nuchal dystonia and dementia. A clinical report on eight cases of “heterogeneous system degeneration”. Trans Am Neurol Assoc 88:25
pubmed: 14272249
Nieforth KA, Golbe LI (1993) Retrospective study of drug response in 87 patients with progressive supranuclear palsy. Clin Neuropharmacol 16(4):338–346
pubmed: 8374914
doi: 10.1097/00002826-199308000-00006
Tan E, Chan L, Wong M (2003) Levodopa-induced oromandibular dystonia in progressive supranuclear palsy. Clin Neurol Neurosurg 105(2):132–134
pubmed: 12691807
doi: 10.1016/S0303-8467(02)00128-2
Lang AE (2005) Treatment of progressive supranuclear palsy and corticobasal degeneration. Mov Disord: Off J Mov Disord Soc 20(S12):S83–S91
doi: 10.1002/mds.20545
Litvan I, Bhatia KP, Burn DJ, Goetz CG, Lang AE, McKeith I et al (2003) Movement disorders society scientific issues committee report: SIC task force appraisal of clinical diagnostic criteria for parkinsonian disorders. Mov Disord: Off J Mov Disord Soc 18(5):467–486
doi: 10.1002/mds.10459
Donker Kaat L, Boon AJ, Kamphorst W, Ravid R, Duivenvoorden HJ, van Swieten JC (2007) Frontal presentation in progressive supranuclear palsy. Neurology 69(8):723–729
pubmed: 17709703
doi: 10.1212/01.wnl.0000267643.24870.26
Josephs KA, Petersen RC, Knopman DS, Boeve BF, Whitwell JL, Duffy JR et al (2006) Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology 66(1):41–48
pubmed: 16401843
doi: 10.1212/01.wnl.0000191307.69661.c3
Mochizuki A, Ueda Y, Komatsuzaki Y, Tsuchiya K, Arai T, Shoji S (2003) Progressive supranuclear palsy presenting with primary progressive aphasia--clinicopathological report of an autopsy case. Acta Neuropathol 105(6):610–614
pubmed: 12669238
doi: 10.1007/s00401-003-0682-5
Tsuboi Y, Josephs KA, Boeve BF, Litvan I, Caselli RJ, Caviness JN et al (2005) Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome. Mov Disord 20(8):982–988
pubmed: 15834857
doi: 10.1002/mds.20478
Compta Y, Valldeoriola F, Tolosa E, Rey MJ, Martí MJ, Valls-Solé J (2007) Long lasting pure freezing of gait preceding progressive supranuclear palsy: a clinicopathological study. Mov Disord 22(13):1954–1958
pubmed: 17724746
doi: 10.1002/mds.21612
Facheris MF, Maniak S, Scaravilli F, Schüle B, Klein C, Pramstaller PP (2008) Pure akinesia as initial presentation of PSP: a clinicopathological study. Parkinsonism Relat Disord 14(6):517–519
pubmed: 18325816
doi: 10.1016/j.parkreldis.2007.11.004
Kurz C, Ebersbach G, Respondek G, Giese A, Arzberger T, Höglinger GU (2016) An autopsy-confirmed case of progressive supranuclear palsy with predominant postural instability. Acta Neuropathol Commun 4(1):120
pubmed: 27842578
pmcid: 5109838
doi: 10.1186/s40478-016-0391-7
Kanazawa M, Shimohata T, Toyoshima Y, Tada M, Kakita A, Morita T et al (2009) Cerebellar involvement in progressive supranuclear palsy: a clinicopathological study. Mov Disord: Off J Mov Disord Soc 24(9):1312–1318
doi: 10.1002/mds.22583
Kanazawa M, Tada M, Onodera O, Takahashi H, Nishizawa M, Shimohata T (2013) Early clinical features of patients with progressive supranuclear palsy with predominant cerebellar ataxia. Parkinsonism Relat Disord 19(12):1149–1151
pubmed: 23916652
doi: 10.1016/j.parkreldis.2013.07.019
Ali F, Martin PR, Botha H, Ahlskog JE, Bower JH, Masumoto JY et al (2019) Sensitivity and specificity of diagnostic criteria for progressive supranuclear palsy. Mov Disord 34(8):1144–1153
Ali F, Botha H, Whitwell JL, Josephs KA (2019) Utility of the movement disorders society criteria for progressive supranuclear palsy in clinical practice. Mov Disord Clin Pract 6(6):436–439
pubmed: 31392243
pmcid: 6660232
doi: 10.1002/mdc3.12807
Shoeibi A, Litvan I, Juncos JL, Bordelon Y, Riley D, Standaert D et al (2019) Are the International Parkinson disease and Movement Disorder Society progressive supranuclear palsy (IPMDS-PSP) diagnostic criteria accurate enough to differentiate common PSP phenotypes? Parkinsonism Relat Disord. In Press
Ahmed Z, Josephs KA, Gonzalez J, DelleDonne A, Dickson DW (2008) Clinical and neuropathologic features of progressive supranuclear palsy with severe pallido-nigro-luysial degeneration and axonal dystrophy. Brain 131(Pt 2):460–472
pubmed: 18158316
doi: 10.1093/brain/awm301
Dickson DW, Ahmed Z, Algom AA, Tsuboi Y, Josephs KA (2010) Neuropathology of variants of progressive supranuclear palsy. Curr Opin Neurol 23(4):394–400
pubmed: 20610990
doi: 10.1097/WCO.0b013e32833be924
Ishizawa K, Lin WL, Tiseo P, Honer WG, Davies P, Dickson DW (2000) A qualitative and quantitative study of grumose degeneration in progressive supranuclear palsy. J Neuropathol Exp Neurol 59(6):513–524
pubmed: 10850864
doi: 10.1093/jnen/59.6.513
Ishizawa K, Dickson DW (2001) Microglial activation parallels system degeneration in progressive supranuclear palsy and corticobasal degeneration. J Neuropathol Exp Neurol 60(6):647–657
pubmed: 11398841
doi: 10.1093/jnen/60.6.647
Gibb WR, Luthert PJ, Marsden CD (1989) Corticobasal degeneration. Brain 112(Pt 5):1171–1192
pubmed: 2478251
doi: 10.1093/brain/112.5.1171
Dickson DW, Yen SH, Suzuki KI, Davies P, Garcia JH, Hirano A (1986) Ballooned neurons in select neurodegenerative diseases contain phosphorylated neurofilament epitopes. Acta Neuropathol 71(3–4):216–223
pubmed: 2432750
doi: 10.1007/BF00688042
Rebeiz JJ, Kolodny EH, Richardson EP Jr (1967) Corticodentatonigral degeneration with neuronal achromasia: a progressive disorder of late adult life. Trans Am Neurol Assoc 92:23–26
pubmed: 5634049
Ksiezak-Reding H, Morgan K, Mattiace LA, Davies P, Liu WK, Yen SH et al (1994) Ultrastructure and biochemical composition of paired helical filaments in corticobasal degeneration. Am J Pathol 145(6):1496–1508
pubmed: 7992852
pmcid: 1887493
Mori H, Nishimura M, Namba Y, Oda M (1994) Corticobasal degeneration: a disease with widespread appearance of abnormal tau and neurofibrillary tangles, and its relation to progressive supranuclear palsy. Acta Neuropathol 88(2):113–121
pubmed: 7985491
doi: 10.1007/BF00294503
Uchihara T, Mitani K, Mori H, Kondo H, Yamada M, Ikeda K (1994) Abnormal cytoskeletal pathology peculiar to corticobasal degeneration is different from that of Alzheimer’s disease or progressive supranuclear palsy. Acta Neuropathol 88(4):379–383
pubmed: 7839832
doi: 10.1007/BF00310383
Feany MB, Dickson DW (1995) Widespread cytoskeletal pathology characterizes corticobasal degeneration. Am J Pathol 146(6):1388–1396
pubmed: 7778678
pmcid: 1870913
Kouri N, Murray ME, Hassan A, Rademakers R, Uitti RJ, Boeve BF et al (2011) Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome. Brain 134(Pt 11):3264–3275
pubmed: 21933807
pmcid: 3212714
doi: 10.1093/brain/awr234
Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B et al (2013) Criteria for the diagnosis of corticobasal degeneration. Neurology 80(5):496–503
pubmed: 23359374
pmcid: 3590050
doi: 10.1212/WNL.0b013e31827f0fd1
Boeve BF (2011) The multiple phenotypes of corticobasal syndrome and corticobasal degeneration: implications for further study. J Mol Neuro: MN 45(3):350–353
doi: 10.1007/s12031-011-9624-1
Lee SE, Rabinovici GD, Mayo MC, Wilson SM, Seeley WW, DeArmond SJ et al (2011) Clinicopathological correlations in corticobasal degeneration. Ann Neurol 70(2):327–340
pubmed: 21823158
pmcid: 3154081
doi: 10.1002/ana.22424
Schneider J, Watts R, Gearing M, Brewer R, Mirra S (1997) Corticobasal degeneration neuropathologic and clinical heterogeneity. Neurology 48(4):959–968
pubmed: 9109885
doi: 10.1212/WNL.48.4.959
Hu WT, Rippon GW, Boeve BF, Knopman DS, Petersen RC, Parisi JE et al (2009) Alzheimer’s disease and corticobasal degeneration presenting as corticobasal syndrome. Mov Disord: Off J Mov Disord Soc 24(9):1375–1379
doi: 10.1002/mds.22574
Chand P, Grafman J, Dickson D, Ishizawa K, Litvan I (2006) Alzheimer’s disease presenting as corticobasal syndrome. Mov Disord: Off J Mov Disord Soc 21(11):2018–2022
doi: 10.1002/mds.21055
Wenning GK, Litvan I, Jankovic J, Granata R, Mangone CA, McKee A et al (1998) Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry 64(2):184–189
pubmed: 9489528
pmcid: 2169933
doi: 10.1136/jnnp.64.2.184
Litvan I, Agid Y, Goetz C, Jankovic J, Wenning GK, Brandel JP et al (1997) Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study. Neurology 48(1):119–125
pubmed: 9008506
doi: 10.1212/WNL.48.1.119
Togasaki DM, Tanner CM (2000) Epidemiologic aspects. Adv Neurol 82:53–59
pubmed: 10624470
Tsuchiya K, Murayama S, Mitani K, Oda T, Arima K, Mimura M et al (2005) Constant and severe involvement of Betz cells in corticobasal degeneration is not consistent with pyramidal signs: a clinicopathological study of ten autopsy cases. Acta Neuropathol 109(4):353–366
pubmed: 15735950
doi: 10.1007/s00401-004-0966-4
Josephs KA, Rossor MN (2004) The alien limb. Pract Neurol 4(1):44–45
doi: 10.1111/j.1474-7766.2004.06-189.x
Grimes DA, Lang AE, Bergeron CB (1999) Dementia as the most common presentation of cortical-basal ganglionic degeneration. Neurology 53(9):1969–1974
pubmed: 10599767
doi: 10.1212/WNL.53.9.1969
Kompoliti K, Goetz C, Boeve BF, Maraganore D, Ahlskog J, Marsden C et al (1998) Clinical presentation and pharmacological therapy in corticobasal degeneration. Arch Neurol 55(7):957–961
pubmed: 9678313
doi: 10.1001/archneur.55.7.957
Boeve BF, Lang AE, Litvan I (2003) Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol: Off J Am Neurol Assoc Child Neurol Soc 54(S5):S15–SS9
doi: 10.1002/ana.10570
Murray R, Neumann M, Forman M, Farmer J, Massimo L, Rice A et al (2007) Cognitive and motor assessment in autopsy-proven corticobasal degeneration. Neurology 68(16):1274–1283
pubmed: 17438218
doi: 10.1212/01.wnl.0000259519.78480.c3
Jacobs DH, Adair JC, Macauley B, Gold M, Rothi LJG, Heilman KM (1999) Apraxia in corticobasal degeneration. Brain Cogn 40(2):336–354
pubmed: 10413565
doi: 10.1006/brcg.1999.1085
Reich SG, Grill SE (2009) Corticobasal degeneration. Curr Treat Options Neurol 11(3):179
pubmed: 19364452
doi: 10.1007/s11940-009-0021-9
Spotorno N, McMillan CT, Powers JP, Clark R, Grossman M (2014) Counting or chunking? Mathematical and heuristic abilities in patients with corticobasal syndrome and posterior cortical atrophy. Neuropsychologia 64:176–183
pubmed: 25278132
pmcid: 4379143
doi: 10.1016/j.neuropsychologia.2014.09.030
Josephs KA, Duffy JR, Strand EA, Whitwell JL, Layton KF, Parisi JE et al (2006) Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain 129(Pt 6):1385–1398
pubmed: 16613895
pmcid: 2748312
doi: 10.1093/brain/awl078
Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC et al (2009) Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol 65(4):403–413
pubmed: 19296504
pmcid: 2696350
doi: 10.1002/ana.21610
Ling H, Gelpi E, Davey K, Jaunmuktane Z, Mok KY, Jabbari E et al Fulminant corticobasal degeneration: a distinct variant with predominant neuronal tau aggregates. Acta Neuropathol:1–18
Rodriguez-Porcel F, Lowder L, Rademakers R, Ravenscroft T, Ghetti B, Hagen MC et al (2016) Fulminant corticobasal degeneration: Agrypnia excitata in corticobasal syndrome. Neurology 86(12):1164–1166
pubmed: 26873956
pmcid: 4820130
doi: 10.1212/WNL.0000000000002491
Litvan I, Lees PS, Cunningham CR, Rai SN, Cambon AC, Standaert DG et al (2016) Environmental and occupational risk factors for progressive supranuclear palsy: case-control study. Mov Disord 31(5):644–652
pubmed: 26854325
pmcid: 4861658
doi: 10.1002/mds.26512
Kelley KD, Checkoway H, Hall DA, Reich SG, Cunningham C, Litvan I (2018) Traumatic brain injury and firearm use and risk of progressive supranuclear palsy among veterans. Front Neurol 9:474
pubmed: 29973911
pmcid: 6020251
doi: 10.3389/fneur.2018.00474
Caparros-Lefebvre D, Golbe LI, Deramecourt V, Maurage CA, Huin V, Buee-Scherrer V et al (2015) A geographical cluster of progressive supranuclear palsy in northern France. Neurology 85(15):1293–1300
pubmed: 26354981
pmcid: 4617163
doi: 10.1212/WNL.0000000000001997
Caparros-Lefebvre D, Sergeant N, Lees A, Camuzat A, Daniel S, Lannuzel A et al (2002) Guadeloupean parkinsonism: a cluster of progressive supranuclear palsy-like tauopathy. Brain 125(Pt 4):801–811
pubmed: 11912113
doi: 10.1093/brain/awf086
Lannuzel A, Ruberg M, Michel PP (2008) Atypical parkinsonism in the Caribbean island of Guadeloupe: etiological role of the mitochondrial complex I inhibitor annonacin. Mov Disord: Off J Mov Disord Soc 23(15):2122–2128
doi: 10.1002/mds.22300
Park HK, Ilango S, Charriez CM, Checkoway H, Riley D, Standaert DG et al (2018) Lifetime exposure to estrogen and progressive supranuclear palsy: environmental and genetic PSP study. Mov Disord 33(3):468–472
pubmed: 29460982
pmcid: 5840026
doi: 10.1002/mds.27336
Kouri N, Ross OA, Dombroski B, Younkin CS, Serie DJ, Soto-Ortolaza A et al (2015) Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. Nat Commun 6:7247
pubmed: 26077951
pmcid: 4469997
doi: 10.1038/ncomms8247
Rohrer JD, Paviour D, Vandrovcova J, Hodges J, De Silva R, Rossor MN (2011) Novel L284R MAPT mutation in a family with an autosomal dominant progressive supranuclear palsy syndrome. Neurodegener Dis 8(3):149–152
pubmed: 20838030
doi: 10.1159/000319454
Ogaki K, Li Y, Takanashi M, Ishikawa K-I, Kobayashi T, Nonaka T et al (2013) Analyses of the MAPT, PGRN, and C9orf72 mutations in Japanese patients with FTLD, PSP, and CBS. Parkinsonism Relat Disord 19(1):15–20
pubmed: 22818528
doi: 10.1016/j.parkreldis.2012.06.019
pmcid: 22818528
Ahmed S, Fairen MD, Sabir MS, Pastor P, Ding J, Ispierto L et al (2019) MAPT p.V363I mutation: a rare cause of corticobasal degeneration. Neurology Genetics 5(4):e347
pubmed: 31404212
pmcid: 6659135
doi: 10.1212/NXG.0000000000000347
Boeve BF, Hutton M (2008) Refining frontotemporal dementia with parkinsonism linked to chromosome 17: introducing FTDP-17 (MAPT) and FTDP-17 (PGRN). Arch Neurol 65(4):460–464
pubmed: 18413467
pmcid: 2746630
doi: 10.1001/archneur.65.4.460
Baker M, Litvan I, Houlden H, Adamson J, Dickson D, Perez-Tur J et al (1999) Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet 8(4):711–715
pubmed: 10072441
doi: 10.1093/hmg/8.4.711
Houlden H, Baker M, Morris H, MacDonald N (2001) Pickering–Brown S, Adamson J, et al. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology 56(12):1702–1706
pubmed: 11425937
doi: 10.1212/WNL.56.12.1702
Höglinger GU, Melhem NM, Dickson DW, Sleiman PM, Wang L-S, Klei L et al (2011) Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet 43(7):699
pubmed: 21685912
pmcid: 3125476
doi: 10.1038/ng.859
Yokoyama JS, Karch CM, Fan CC, Bonham LW, Kouri N, Ross OA et al (2017) Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia. Acta Neuropathol 133(5):825–837
pubmed: 28271184
pmcid: 5429027
doi: 10.1007/s00401-017-1693-y
Wendler F, Tooze S (2001) Syntaxin 6: the promiscuous behaviour of a SNARE protein. Traffic 2(9):606–611
pubmed: 11555414
doi: 10.1034/j.1600-0854.2001.20903.x
Harding HP, Zhang Y, Bertolotti A, Zeng H, Ron D (2000) Perk is essential for translational regulation and cell survival during the unfolded protein response. Mol Cell 5(5):897–904
pubmed: 10882126
doi: 10.1016/S1097-2765(00)80330-5
Yuan SH, Hiramatsu N, Liu Q, Sun XV, Lenh D, Chan P et al (2018) Tauopathy-associated PERK alleles are functional hypomorphs that increase neuronal vulnerability to ER stress. Hum Mol Genet 27(22):3951–3963
pubmed: 30137327
pmcid: 6216228
Sanchez-Contreras MY, Kouri N, Cook CN, Serie DJ, Heckman MG, Finch NA et al (2018) Replication of progressive supranuclear palsy genome-wide association study identifies SLCO1A2 and DUSP10 as new susceptibility loci. Mol Neurodegener 13(1):37
pubmed: 29986742
pmcid: 6038352
doi: 10.1186/s13024-018-0267-3
Albers DS, Augood SJ, Martin DM, Standaert DG, Vonsattel JPG, Beal MF (1999) Evidence for oxidative stress in the subthalamic nucleus in progressive supranuclear palsy. J Neurochem 73(2):881–884
pubmed: 10428088
doi: 10.1046/j.1471-4159.1999.0730881.x
Albers DS, Augood SJ, Park LC, Browne SE, Martin DM, Adamson J et al (2000) Frontal lobe dysfunction in progressive supranuclear palsy: evidence for oxidative stress and mitochondrial impairment. J Neurochem 74(2):878–881
pubmed: 10646541
doi: 10.1046/j.1471-4159.2000.740878.x
Albers DS, Swerdlow RH, Manfredi G, Gajewski C, Yang L, Parker WD Jr et al (2001) Further evidence for mitochondrial dysfunction in progressive supranuclear palsy. Exp Neurol 168(1):196–198
pubmed: 11170735
doi: 10.1006/exnr.2000.7607
Park LC, Albers DS, Xu H, Lindsay JG, Beal MF, Gibson GE (2001) Mitochondrial impairment in the cerebellum of the patients with progressive supranuclear palsy. J Neurosci Res 66(5):1028–1034
pubmed: 11746433
doi: 10.1002/jnr.10062
Albers DS, Beal MF (2002) Mitochondrial dysfunction in progressive supranuclear palsy. Neurochem Int 40(6):559–564
pubmed: 11850113
doi: 10.1016/S0197-0186(01)00126-7
Cantuti-Castelvetri I, Keller-McGandy CE, Albers DS, Beal MF, Vonsattel J-P, Standaert DG et al (2002) Expression and activity of antioxidants in the brain in progressive supranuclear palsy. Brain Res 930(1–2):170–181
pubmed: 11879807
doi: 10.1016/S0006-8993(02)02244-8
Martinelli P, Scaglione C, Lodi R, Iotti S, Barbiroli B (2000) Deficit of brain and skeletal muscle bioenergetics in progressive supranuclear palsy shown in vivo by phosphorus magnetic resonance spectroscopy. Mov Disord 15(5):889–893
pubmed: 11009196
doi: 10.1002/1531-8257(200009)15:5<889::AID-MDS1020>3.0.CO;2-T
Fernandez-Botran R, Ahmed Z, Crespo FA, Gatenbee C, Gonzalez J, Dickson DW et al (2011) Cytokine expression and microglial activation in progressive supranuclear palsy. Parkinsonism Relat Disord 17(9):683–688
pubmed: 21741294
pmcid: 3196843
doi: 10.1016/j.parkreldis.2011.06.007
Starhof C, Winge K, Heegaard NHH, Skogstrand K, Friis S, Hejl A (2018) Cerebrospinal fluid pro-inflammatory cytokines differentiate parkinsonian syndromes. J Neuroinflammation 15(1):305
pubmed: 30390673
pmcid: 6215346
doi: 10.1186/s12974-018-1339-6
Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F et al (1994) Alterations in glutathione levels in Parkinson’s disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol: Off J Am Neurol Assoc Child Neurol Soc 36(3):348–355
doi: 10.1002/ana.410360305
Iba M, Guo JL, McBride JD, Zhang B, Trojanowski JQ, Lee VM-Y (2013) Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer’s-like tauopathy. J Neurosci 33(3):1024–1037
pubmed: 23325240
pmcid: 3575082
doi: 10.1523/JNEUROSCI.2642-12.2013
Clavaguera F, Lavenir I, Falcon B, Frank S, Goedert M, Tolnay M (2013) “Prion-like” templated misfolding in tauopathies. Brain Pathol 23(3):342–349
pubmed: 23587140
doi: 10.1111/bpa.12044
Clavaguera F, Akatsu H, Fraser G, Crowther RA, Frank S, Hench J et al (2013) Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci 110(23):9535–9540
pubmed: 23690619
doi: 10.1073/pnas.1301175110
Sanders DW, Kaufman SK, DeVos SL, Sharma AM, Mirbaha H, Li A et al (2014) Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82(6):1271–1288
pubmed: 24857020
pmcid: 4171396
doi: 10.1016/j.neuron.2014.04.047
Probst A, Götz J, Wiederhold K, Tolnay M, Mistl C, Jaton A et al (2000) Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. Acta Neuropathol 99(5):469–481
pubmed: 10805089
doi: 10.1007/s004010051148
Dujardin K, Defebvre L, Duhamel A, Lecouffe P, Rogelet P, Steinling M et al (2004) Cognitive and SPECT characteristics predict progression of Parkinson’s disease in newly diagnosed patients. J Neurol 251(11):1383–1392
pubmed: 15592735
doi: 10.1007/s00415-004-0549-2
Clavaguera F, Hench J, Lavenir I, Schweighauser G, Frank S, Goedert M et al (2014) Peripheral administration of tau aggregates triggers intracerebral tauopathy in transgenic mice. Acta Neuropathol 127(2):299–301
pubmed: 24362441
doi: 10.1007/s00401-013-1231-5
Nishimura M, Namba Y, Ikeda K, Oda M (1992) Glial fibrillary tangles with straight tubules in the brains of patients with progressive supranuclear palsy. Neurosci Lett 143(1–2):35–38
pubmed: 1436679
doi: 10.1016/0304-3940(92)90227-X
Yamada T, McGeer P, McGeer E (1992) Appearance of paired nucleated, tau-positive glia in patients with progressive supranuclear palsy brain tissue. Neurosci Lett 135(1):99–102
pubmed: 1371861
doi: 10.1016/0304-3940(92)90145-W
Kato N, Arai K, Hattori T (2003) Study of the rostral midbrain atrophy in progressive supranuclear palsy. J Neurol Sci 210(1–2):57–60
pubmed: 12736089
doi: 10.1016/S0022-510X(03)00014-5
Adachi M, KAWANAMI T, OHSHIMA H, Sugai Y, Hosoya T (2004) Morning glory sign: a particular MR finding in progressive supranuclear palsy. Magn Reson Med Sci 3(3):125–132
pubmed: 16093629
doi: 10.2463/mrms.3.125
Massey LA, Micallef C, Paviour DC, O’sullivan SS, Ling H, Williams DR et al (2012) Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy. Mov Disord 27(14):1754–1762
pubmed: 22488922
doi: 10.1002/mds.24968
Massey LA, Micallef C, Paviour DC, O’Sullivan SS, Ling H, Williams DR et al (2012) Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy. Mov Disord: Off J Mov Disord Soc 27(14):1754–1762
doi: 10.1002/mds.24968
Whitwell JL, Jack CR Jr, Parisi JE, Gunter JL, Weigand SD, Boeve BF et al (2013) Midbrain atrophy is not a biomarker of progressive supranuclear palsy pathology. Eur J Neurol 20(10):1417–1422
pubmed: 23746093
pmcid: 3773014
doi: 10.1111/ene.12212
Massey LA, Jager HR, Paviour DC, O’Sullivan SS, Ling H, Williams DR et al (2013) The midbrain to pons ratio: a simple and specific MRI sign of progressive supranuclear palsy. Neurology 80(20):1856–1861
pubmed: 23616165
pmcid: 3908351
doi: 10.1212/WNL.0b013e318292a2d2
Quattrone A, Nicoletti G, Messina D, Fera F, Condino F, Pugliese P et al (2008) MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. Radiology 246(1):214–221
pubmed: 17991785
doi: 10.1148/radiol.2453061703
Moller L, Kassubek J, Sudmeyer M, Hilker R, Hattingen E, Egger K et al (2017) Manual MRI morphometry in parkinsonian syndromes. Mov Disord: Off J Mov Disord Soc 32(5):778–782
doi: 10.1002/mds.26921
Nigro S, Arabia G, Antonini A, Weis L, Marcante A, Tessitore A et al (2017) Magnetic Resonance Parkinsonism Index: diagnostic accuracy of a fully automated algorithm in comparison with the manual measurement in a large Italian multicentre study in patients with progressive supranuclear palsy. Eur Radiol 27(6):2665–2675
pubmed: 27761709
doi: 10.1007/s00330-016-4622-x
Zanigni S, Calandra-Buonaura G, Manners DN, Testa C, Gibertoni D, Evangelisti S et al (2016) Accuracy of MR markers for differentiating Progressive Supranuclear Palsy from Parkinson’s disease. NeuroImage Clinical 11:736–742
pubmed: 27330973
pmcid: 4908307
doi: 10.1016/j.nicl.2016.05.016
Hussl A, Mahlknecht P, Scherfler C, Esterhammer R, Schocke M, Poewe W et al (2010) Diagnostic accuracy of the magnetic resonance Parkinsonism index and the midbrain-to-pontine area ratio to differentiate progressive supranuclear palsy from Parkinson’s disease and the Parkinson variant of multiple system atrophy. Mov Disord: Off J Mov Disord Soc 25(14):2444–2449
doi: 10.1002/mds.23351
Whitwell JL, Master AV, Avula R, Kantarci K, Eggers SD, Edmonson HA et al (2011) Clinical correlates of white matter tract degeneration in progressive supranuclear palsy. Arch Neurol 68(6):753–760
pubmed: 21670399
pmcid: 3401587
doi: 10.1001/archneurol.2011.107
Whitwell JL, Avula R, Master A, Vemuri P, Senjem ML, Jones DT et al (2011) Disrupted thalamocortical connectivity in PSP: a resting-state fMRI, DTI, and VBM study. Parkinsonism Relat Disord 17(8):599–605
pubmed: 21665514
pmcid: 3168952
doi: 10.1016/j.parkreldis.2011.05.013
Gardner RC, Boxer AL, Trujillo A, Mirsky JB, Guo CC, Gennatas ED et al (2013) Intrinsic connectivity network disruption in progressive supranuclear palsy. Ann Neurol 73(5):603–616
pubmed: 23536287
pmcid: 3732833
doi: 10.1002/ana.23844
Josephs KA, Whitwell JL, Dickson DW, Boeve BF, Knopman DS, Petersen RC et al (2008) Voxel-based morphometry in autopsy proven PSP and CBD. Neurobiol Aging 29(2):280–289
pubmed: 17097770
doi: 10.1016/j.neurobiolaging.2006.09.019
Gröschel K, Hauser T-K, Luft A, Patronas N, Dichgans J, Litvan I et al (2004) Magnetic resonance imaging-based volumetry differentiates progressive supranuclear palsy from corticobasal degeneration. NeuroImage 21(2):714–724
pubmed: 14980574
doi: 10.1016/j.neuroimage.2003.09.070
Hauser RA, Murtaugh FR, Akhter K, Gold M, Olanow C (1996) Magnetic resonance imaging of corticobasal degeneration. J Neuroimaging 6(4):222–226
pubmed: 8903073
doi: 10.1111/jon199664222
Koyama M, Yagishita A, Nakata Y, Hayashi M, Bandoh M, Mizutani T (2007) Imaging of corticobasal degeneration syndrome. Neuroradiology 49(11):905–912
pubmed: 17632713
doi: 10.1007/s00234-007-0265-6
Boxer AL, Geschwind MD, Belfor N, Gorno-Tempini ML, Schauer GF, Miller BL et al (2006) Patterns of brain atrophy that differentiate corticobasal degeneration syndrome from progressive supranuclear palsy. Arch Neurol 63(1):81–86
pubmed: 16401739
doi: 10.1001/archneur.63.1.81
Josephs KA, Tang-Wai DF, Edland SD, Knopman DS, Dickson DW, Parisi JE et al (2004) Correlation between antemortem magnetic resonance imaging findings and pathologically confirmed corticobasal degeneration. Arch Neurol 61(12):1881–1884
pubmed: 15596608
doi: 10.1001/archneur.61.12.1881
Hassan A, Whitwell JL, Boeve BF, Jack CR Jr, Parisi JE, Dickson DW et al (2010) Symmetric corticobasal degeneration (S-CBD). Parkinsonism Relat Disord 16(3):208–214
pubmed: 20018548
doi: 10.1016/j.parkreldis.2009.11.013
Josephs KA, Whitwell JL, Boeve BF, Knopman DS, Petersen RC, Hu WT et al (2010) Anatomical differences between CBS-corticobasal degeneration and CBS-Alzheimer’s disease. Mov Disord: Off J Mov Disord Soc 25(9):1246–1252
doi: 10.1002/mds.23062
Whitwell JL, Jack CR Jr, Boeve BF, Parisi JE, Ahlskog JE, Drubach DA et al (2010) Imaging correlates of pathology in corticobasal syndrome. Neurology 75(21):1879–1887
pubmed: 21098403
pmcid: 2995388
doi: 10.1212/WNL.0b013e3181feb2e8
McMillan CT, Boyd C, Gross RG, Weinstein J, Firn K, Toledo JB et al (2016) Multimodal imaging evidence of pathology-mediated disease distribution in corticobasal syndrome. Neurology 87(12):1227–1234
pubmed: 27543644
pmcid: 5035978
doi: 10.1212/WNL.0000000000003119
Whitwell JL, Jack CR, Parisi JE, Knopman DS, Boeve BF, Petersen RC et al (2011) Imaging signatures of molecular pathology in behavioral variant frontotemporal dementia. J Mol Neurosci 45(3):372
pubmed: 21556732
pmcid: 3401589
doi: 10.1007/s12031-011-9533-3
Whitwell JL, Josephs KA (2011) Neuroimaging in frontotemporal lobar degeneration--predicting molecular pathology. Nat Rev Neurol 8(3):131–142
doi: 10.1038/nrneurol.2012.7
McMillan CT, Irwin DJ, Avants BB, Powers J, Cook PA, Toledo JB et al (2013) White matter imaging helps dissociate tau from TDP-43 in frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry 84(9):949–955
pubmed: 23475817
pmcid: 3737288
doi: 10.1136/jnnp-2012-304418
Botha H, Whitwell JL, Madhaven A, Senjem ML, Lowe V, Josephs KA (2014) The pimple sign of progressive supranuclear palsy syndrome. Parkinsonism Relat Disord 20(2):180–185
pubmed: 24252300
doi: 10.1016/j.parkreldis.2013.10.023
Zalewski N, Botha H, Whitwell JL, Lowe V, Dickson DW, Josephs KA (2014) FDG-PET in pathologically confirmed spontaneous 4R-tauopathy variants. J Neurol 261(4):710–716
pubmed: 24492888
doi: 10.1007/s00415-014-7256-4
Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC (2015) Tau imaging: early progress and future directions. Lancet Neurol 14(1):114–124
pubmed: 25496902
doi: 10.1016/S1474-4422(14)70252-2
Marquié M, Normandin MD, Vanderburg CR, Costantino IM, Bien EA, Rycyna LG et al (2015) Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol 78(5):787–800
pubmed: 26344059
pmcid: 4900162
doi: 10.1002/ana.24517
Passamonti L, Vazquez Rodriguez P, Hong YT, Allinson KS, Williamson D, Borchert RJ et al (2017) 18F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear palsy. Brain 140(3):781–791
pubmed: 28122879
pmcid: 5382948
Pontecorvo MJ, Devous Sr MD, Navitsky M, Lu M, Salloway S, Schaerf FW et al (2017) Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain 140(3):748–763
pubmed: 28077397
pmcid: 5382945
Nasrallah IM, Chen YJ, Hsieh M-K, Phillips JS, Ternes K, Stockbower GE et al (2018) 18F-Flortaucipir PET/MRI correlations in nonamnestic and amnestic variants of Alzheimer disease. J Nucl Med 59(2):299–306
pubmed: 28747523
pmcid: 6348438
doi: 10.2967/jnumed.117.194282
Ossenkoppele R, Schonhaut DR, Schöll M, Lockhart SN, Ayakta N, Baker SL et al (2016) Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease. Brain 139(5):1551–1567
pubmed: 26962052
pmcid: 5006248
doi: 10.1093/brain/aww027
Lowe VJ, Curran G, Fang P, Liesinger AM, Josephs KA, Parisi JE et al (2016) An autoradiographic evaluation of AV-1451 tau PET in dementia. Acta Neuropathol Commun 4(1):58
pubmed: 27296779
pmcid: 4906968
doi: 10.1186/s40478-016-0315-6
Bevan Jones WR, Cope TE, Passamonti L, Fryer TD, Hong YT, Aigbirhio F et al (2016) [18F]AV-1451 PET in behavioral variant frontotemporal dementia due to MAPT mutation. Ann Clin Trans Neurol 3(12):940–947
doi: 10.1002/acn3.366
Cho H, Choi JY, Hwang MS, Lee SH, Ryu YH, Lee MS et al (2017) Subcortical 18 F-AV-1451 binding patterns in progressive supranuclear palsy. Mov Disord: Off J Mov Disord Soc 32(1):134–140
doi: 10.1002/mds.26844
Smith R, Schain M, Nilsson C, Strandberg O, Olsson T, Hagerstrom D et al (2017) Increased basal ganglia binding of 18 F-AV-1451 in patients with progressive supranuclear palsy. Mov Disord: Off J Mov Disord Soc 32(1):108–114
doi: 10.1002/mds.26813
Whitwell JL, Lowe VJ, Tosakulwong N, Weigand SD, Senjem ML, Schwarz CG et al (2017) [18 F]AV-1451 tau positron emission tomography in progressive supranuclear palsy. Mov Disord: Off J Mov Disord Soc 32(1):124–133
doi: 10.1002/mds.26834
Whitwell JL, Tosakulwong N, Botha H, Ali F, Clark HM, Duffy JR et al (2020) Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants. NeuroImage: Clinical 25:102152
doi: 10.1016/j.nicl.2019.102152
McMillan CT, Irwin DJ, Nasrallah I, Phillips JS, Spindler M, Rascovsky K et al (2016) Multimodal evaluation demonstrates in vivo (18)F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration. Acta Neuropathol 132(6):935–937
pubmed: 27815633
pmcid: 5154298
doi: 10.1007/s00401-016-1640-3
Ali F, Whitwell JL, Martin PR, Senjem ML, Knopman DS, Jack CR et al (2018) [(18)F] AV-1451 uptake in corticobasal syndrome: the influence of beta-amyloid and clinical presentation. J Neurol 265(5):1079–1088
pubmed: 29497818
pmcid: 6095646
doi: 10.1007/s00415-018-8815-x
Gerhard A, Trender-Gerhard I, Turkheimer F, Quinn NP, Bhatia KP, Brooks DJ (2006) In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy. Mov Disord: Off J Mov Disord Soc 21(1):89–93
doi: 10.1002/mds.20668
Gerhard A, Watts J, Trender-Gerhard I, Turkheimer F, Banati RB, Bhatia K et al (2004) In vivo imaging of microglial activation with [11C](R)-PK11195 PET in corticobasal degeneration. Mov Disord: Off J Mov Disord Soc 19(10):1221–1226
doi: 10.1002/mds.20162
Arai T, Ikeda K, Akiyama H, Shikamoto Y, Tsuchiya K, Yagishita S et al (2001) Distinct isoforms of tau aggregated in neurons and glial cells in brains of patients with Pick’s disease, corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathol 101(2):167–173
pubmed: 11271372
doi: 10.1007/s004010000283
Urakami K, Wada K, Arai H, Sasaki H, Kanai M, Shoji M et al (2001) Diagnostic significance of tau protein in cerebrospinal fluid from patients with corticobasal degeneration or progressive supranuclear palsy. J Neurol Sci 183(1):95–98
pubmed: 11166802
doi: 10.1016/S0022-510X(00)00480-9
Hall S, Öhrfelt A, Constantinescu R, Andreasson U, Surova Y, Bostrom F et al (2012) Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 69(11):1445–1452
pubmed: 22925882
doi: 10.1001/archneurol.2012.1654
Borroni B, Malinverno M, Gardoni F, Alberici A, Parnetti L, Premi E et al (2008) Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy. Neurology 71(22):1796–1803
pubmed: 18971445
doi: 10.1212/01.wnl.0000335941.68602.39
Kuiperij HB, Borroni B, Verbeek MM, Gardoni F, Malinverno M, Padovani A et al (2011) Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy. Neurology 76(16):1443
pubmed: 21502610
doi: 10.1212/WNL.0b013e318210e671
Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T et al (2018) Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol:1
Hansson O, Janelidze S, Hall S, Magdalinou N, Lees AJ, Andreasson U et al (2017) Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder. Neurology 88(10):930–937
pubmed: 28179466
pmcid: 5333515
doi: 10.1212/WNL.0000000000003680
Holmberg B, Rosengren L, Karlsson JE, Johnels B (1998) Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson’s disease. Mov Disord: Off J Mov Disord Soc 13(1):70–77
doi: 10.1002/mds.870130116
Marques TM, van Rumund A, Oeckl P, Kuiperij HB, Esselink RA, Bloem BR et al (2019) Serum NFL discriminates Parkinson disease from atypical parkinsonisms. Neurology 92(13):e1479–e1e86
pubmed: 30814322
doi: 10.1212/WNL.0000000000007179
Sako W, Murakami N, Izumi Y, Kaji R (2015) Neurofilament light chain level in cerebrospinal fluid can differentiate Parkinson’s disease from atypical parkinsonism: evidence from a meta-analysis. J Neurol Sci 352(1–2):84–87
pubmed: 25868897
doi: 10.1016/j.jns.2015.03.041
Rojas JC, Karydas A, Bang J, Tsai RM, Blennow K, Liman V et al (2016) Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann Neurol: Off J Am Neurol Assoc Child Neurol Soc 3(3):216–225
Kuhle J, Barro C, Andreasson U, Derfuss T, Lindberg R, Sandelius A et al (2016) Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med 54(10):1655–1661
pubmed: 27071153
doi: 10.1515/cclm-2015-1195
Groveman BR, Orrù CD, Hughson AG, Raymond LD, Zanusso G, Ghetti B et al (2018) Rapid and ultra-sensitive quantitation of disease-associated α-synuclein seeds in brain and cerebrospinal fluid by αSyn RT-QuIC. Acta Neuropathol Commun 6(1):7
pubmed: 29422107
pmcid: 5806364
doi: 10.1186/s40478-018-0508-2
Kraus A, Saijo E, Metrick MA 2nd, Newell K, Sigurdson CJ, Zanusso G et al (2019) Seeding selectivity and ultrasensitive detection of tau aggregate conformers of Alzheimer disease. Acta Neuropathol 137(4):585–598
pubmed: 30570675
doi: 10.1007/s00401-018-1947-3
Saijo E, Ghetti B, Zanusso G, Oblak A, Furman JL, Diamond MI et al (2017) Ultrasensitive and selective detection of 3-repeat tau seeding activity in Pick disease brain and cerebrospinal fluid. Acta Neuropathol 133(5):751–765
pubmed: 28293793
doi: 10.1007/s00401-017-1692-z
Saijo E, Metrick MA, Koga S, Parchi P, Litvan I, Spina S et al (2020) 4-repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration. Acta Neuropathol 139(1):63–77
pubmed: 31616982
doi: 10.1007/s00401-019-02080-2
Riley D, Lang A, Ae L, Resch L, Ashby P, Hornykiewicz O et al (1990) Cortical-basal ganglionic degeneration. Neurology 40(8):1203
pubmed: 2381527
doi: 10.1212/WNL.40.8.1203
Jackson JA, Jankovic J, Ford J (1983) Progressive supranuclear palsy: clinical features and response to treatment in 16 patients. Ann Neurol: Off J Am Neurol Assoc Child Neurol Soc 13(3):273–278
doi: 10.1002/ana.410130308
Stowe R, Ives N, Clarke CE, Ferreira J, Hawker RJ, Shah L et al (2008) Dopamine agonist therapy in early Parkinson’s disease. Cochrane Database Syst Rev (2):CD006564
Kompoliti K, Goetz C, Litvan I, Jellinger K, Verny M (1998) Pharmacological therapy in progressive supranuclear palsy. Arch Neurol 55(8):1099–1102
pubmed: 9708960
doi: 10.1001/archneur.55.8.1099
Engel PA (1996) Treatment of progressive supranuclear palsy with amitriptyline: therapeutic and toxic effects. J Am Geriatr Soc 44(9):1072–1074
pubmed: 8790233
doi: 10.1111/j.1532-5415.1996.tb02940.x
Rajrut A, Uitti R, Fenton M, George D (1997) Amantadine effectiveness in multiple system atrophy and progressive supranuclear palsy. Parkinsonism Relat Disord 3(4):211–214
pubmed: 18591078
doi: 10.1016/S1353-8020(97)00022-9
Daniele A, Moro E, Bentivoglio AR (1999) Zolpidem in progressive supranuclear palsy. N Engl J Med 341(7):543–544
pubmed: 10447452
doi: 10.1056/NEJM199908123410721
Cotter C, Armytage T, Crimmins D (2010) The use of zolpidem in the treatment of progressive supranuclear palsy. J Clin Neurosci 17(3):385–386
pubmed: 20071178
doi: 10.1016/j.jocn.2009.05.038
Mayr BJ, Bonelli RM, Niederwieser G, Költringer P, Reisecker F (2002) Zolpidem in progressive supranuclear palsy. Eur J Neurol 9(2):184–185
pubmed: 11882066
doi: 10.1046/j.1468-1331.2002.0354g.x
Müller J, Wenning G, Wissel J, Seppi K, Poewe W (2002) Botulinum toxin treatment in atypical parkinsonian disorders associated with disabling focal dystonia. J Neurol 249(3):300–304
pubmed: 11993530
doi: 10.1007/s004150200009
Piccione F, Mancini E, Tonin P, Bizzarini M (1997) Botulinum toxin treatment of apraxia of eyelid opening in progressive supranuclear palsy: report of two cases. Arch Phys Med Rehabil 78(5):525–529
pubmed: 9161374
doi: 10.1016/S0003-9993(97)90169-6
Vanek Z, Jankovic J (2001) Dystonia in corticobasal degeneration. Mov Disord: Off J Mov Disord Soc 16(2):252–257
doi: 10.1002/mds.1038
Polo KB, Jabbari B (1994) Botulinum toxin-A improves the rigidity of progressive supranuclear palsy. Ann Neurol: Off J Am Neurol Assoc Child Neurol Soc 35(2):237–239
doi: 10.1002/ana.410350218
Boeve BF, Josephs KA, Drubach DA (2008) Current and future management of the corticobasal syndrome and corticobasal degeneration. Handb Clin Neurol 89:533–548
pubmed: 18631775
doi: 10.1016/S0072-9752(07)01249-3
Kovács T, Farsang M, Vitaszil E, Barsi P, Györke T, Szirmai I et al (2009) Levetiracetam reduces myoclonus in corticobasal degeneration: report of two cases. J Neural Transm 116(12):1631
pubmed: 19756367
doi: 10.1007/s00702-009-0301-2
Gómez-Caravaca MT, Cáceres-Redondo MT, Huertas-Fernández I, Vargas-González L, Carrillo F, Carballo M et al (2015) The use of botulinum toxin in the treatment of sialorrhea in parkinsonian disorders. Neurol Sci 36(2):275–279
pubmed: 25238916
doi: 10.1007/s10072-014-1950-y
Hyson HC, Johnson AM, Jog MS (2002) Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. Mov Disord: Off J Mov Disord Soc 17(6):1318–1320
doi: 10.1002/mds.10276
Litvan I, Phipps M, Pharr VL, Hallett M, Grafman J, Salazar A (2001) Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology 57(3):467–473
pubmed: 11502915
doi: 10.1212/WNL.57.3.467
Mendez MF, Shapira JS, McMurtray A, Licht E (2007) Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry 15(1):84–87
pubmed: 17194818
doi: 10.1097/01.JGP.0000231744.69631.33
Boxer AL, Knopman DS, Kaufer DI, Grossman M, Onyike C, Graf-Radford N et al (2013) Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 12(2):149–156
pubmed: 23290598
pmcid: 3756890
doi: 10.1016/S1474-4422(12)70320-4
Boxer AL, Lipton AM, Womack K, Merrilees J, Neuhaus J, Pavlic D et al (2009) An open label study of memantine treatment in three subtypes of frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord 23(3):211
pubmed: 19812461
pmcid: 2760056
doi: 10.1097/WAD.0b013e318197852f
Pattee GL, Wymer JP, Lomen-Hoerth C, Appel SH, Formella AE, Pope LE (2014) An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions. Curr Med Res Opin 30(11):2255–2265
pubmed: 25062507
pmcid: 4743597
doi: 10.1185/03007995.2014.940040
Clerici I, Ferrazzoli D, Maestri R, Bossio F, Zivi I, Canesi M et al (2017) Rehabilitation in progressive supranuclear palsy: effectiveness of two multidisciplinary treatments. PLoS One 12(2):e0170927
pubmed: 28158197
pmcid: 5291505
doi: 10.1371/journal.pone.0170927
Zampieri C, Di Fabio RP (2008) Balance and eye movement training to improve gait in people with progressive supranuclear palsy: quasi-randomized clinical trial. Phys Ther 88(12):1460–1473
pubmed: 18948373
doi: 10.2522/ptj.20070302
Steffen TM, Boeve BF, Mollinger-Riemann LA, Petersen CM (2007) Long-term locomotor training for gait and balance in a patient with mixed progressive supranuclear palsy and corticobasal degeneration. Phys Ther 87(8):1078–1087
pubmed: 17578939
doi: 10.2522/ptj.20060166
Henry M, Meese M, Truong S, Babiak M, Miller B, Gorno-Tempini M (2013) Treatment for apraxia of speech in nonfluent variant primary progressive aphasia. Behav Neurol 26(1–2):77–88
pubmed: 22713405
pmcid: 3651677
doi: 10.1155/2013/824302
Farrajota L, Maruta C, Maroco J, Martins IP, Guerreiro M, De Mendonca A (2012) Speech therapy in primary progressive aphasia: a pilot study. Dement Geriatr Cogn Disord Extra 2(1):321–331
doi: 10.1159/000341602
Wiblin L, Lee M, Burn D (2017) Palliative care and its emerging role in multiple system atrophy and progressive supranuclear palsy. Parkinsonism Relat Disord 34:7–14
pubmed: 28341224
doi: 10.1016/j.parkreldis.2016.10.013
Buée L, Bussière T, Buée-Scherrer V, Delacourte A, Hof PR (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Rev 33(1):95–130
pubmed: 10967355
doi: 10.1016/S0165-0173(00)00019-9
Leclair-Visonneau L, Rouaud T, Debilly B, Durif F, Houeto JL, Kreisler A et al (2016) Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy. Clin Neurol Neurosurg 146:35–39
pubmed: 27136096
doi: 10.1016/j.clineuro.2016.04.021
Min S-W, Chen X, Tracy TE, Li Y, Zhou Y, Wang C et al (2015) Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat Med 21(10):1154
pubmed: 26390242
pmcid: 4598295
doi: 10.1038/nm.3951
Yuzwa SA, Shan X, Macauley MS, Clark T, Skorobogatko Y, Vosseller K et al (2012) Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. Nat Chem Biol 8(4):393–399
pubmed: 22366723
doi: 10.1038/nchembio.797
Wang AC, Jensen EH, Rexach JE, Vinters HV, Hsieh-Wilson LC (2016) Loss of O-GlcNAc glycosylation in forebrain excitatory neurons induces neurodegeneration. Proc Natl Acad Sci U S A 113(52):15120–15125
pubmed: 27956640
pmcid: 5206508
doi: 10.1073/pnas.1606899113
Boxer AL, Lang AE, Grossman M, Knopman DS, Miller BL, Schneider LS et al (2014) Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol 13(7):676–685
pubmed: 24873720
pmcid: 4129545
doi: 10.1016/S1474-4422(14)70088-2
Boxer AMZ, Tsai R, Koestler M, Rojas J, Ljubenkov P, Rosen H et al (2017) A phase 1B, randomized, double-blind, placebo-controlled, sequential cohort, dose-ranging study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of TPI 287 (abeotaxane) in patients with primary four repeat tauopathies: corticobasal syndrome or progressive supranuclear palsy; or the secondary tauopathy, Alzheimer’s disease. J Prev Alz Dis 4(4):282–428
Zhang B, Carroll J, Trojanowski JQ, Yao Y, Iba M, Potuzak JS et al (2012) The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J Neurosci Off J Soc Neurosci 32(11):3601–3611
doi: 10.1523/JNEUROSCI.4922-11.2012
Wischik CM, Staff RT, Wischik DJ, Bentham P, Murray AD, Storey JM et al (2015) Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer’s disease. J Alzheimer’s Disease: JAD 44(2):705–720
doi: 10.3233/JAD-142874
Bensimon G, Ludolph A, Agid Y, Vidailhet M, Payan C, Leigh PN (2009) Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain 132(Pt 1):156–171
pubmed: 19029129
doi: 10.1093/brain/awn291
Apetauerova D, Scala SA, Hamill RW, Simon DK, Pathak S, Ruthazer R et al (2016) CoQ10 in progressive supranuclear palsy: a randomized, placebo-controlled, double-blind trial. Neurology(R) Neuroimmunol Neuroinflammation 3(5):e266
doi: 10.1212/NXI.0000000000000266
Nuebling G, Hensler M, Paul S, Zwergal A, Crispin A, Lorenzl S (2016) PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy. J Neurol 263(8):1565–1574
pubmed: 27230855
doi: 10.1007/s00415-016-8169-1
Stamelou M, Reuss A, Pilatus U, Magerkurth J, Niklowitz P, Eggert KM et al (2008) Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov Disord: Off J Mov Disord Soc 23(7):942–949
doi: 10.1002/mds.22023
Bright J, Hussain S, Dang V, Wright S, Cooper B, Byun T et al (2015) Human secreted tau increases amyloid-beta production. Neurobiol Aging 36(2):693–709
pubmed: 25442111
doi: 10.1016/j.neurobiolaging.2014.09.007
Qureshi IA, Tirucherai G, Ahlijanian MK, Kolaitis G, Bechtold C, Grundman M (2018) A randomized, single ascending dose study of intravenous BIIB092 in healthy participants. Alzheimer’s & Dement: Transl Res Clin Interv 4:746–755
doi: 10.1016/j.trci.2018.10.007
Boxer AL, Qureshi I, Ahlijanian M, Grundman M, Golbe LI, Litvan I et al (2019) Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. Lancet Neurol 18(6):549–558
doi: 10.1016/S1474-4422(19)30139-5
Dam T, Boxer A, Golbe LI, Höglinger G, Morris HR, Litvan I et al (2018) Efficacy and safety of BIIB092 in patients with progressive supranuclear palsy: passport phase 2 study design (P6. 073). AAN Enterprises
Budur K, West T, Braunstein JB, Fogelman I, Bordelon YM, Litvan I et al (2017) Results of a phase 1, single ascending dose, placebo-controlled study of ABBV-8E12 in patients with progressive supranuclear palsy and phase 2 study design in early Alzheimer’s disease. Alzheimers Dement 13(7):P599–P600
doi: 10.1016/j.jalz.2017.07.241
West T, Hu Y, Verghese P, Bateman R, Braunstein J, Fogelman I et al (2017) Preclinical and clinical development of ABBV-8E12, a humanized anti-tau antibody, for treatment of Alzheimer’s disease and other tauopathies. J Prev Alzheimers Dis 4(04):236–241
pubmed: 29181488
Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM (2011) Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem 118(4):658–667
pubmed: 21644996
pmcid: 3366469
doi: 10.1111/j.1471-4159.2011.07337.x
Chai X, Wu S, Murray TK, Kinley R, Cella CV, Sims H et al (2011) Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J Biol Chem 286(39):34457–34467
pubmed: 21841002
pmcid: 3190817
doi: 10.1074/jbc.M111.229633
Sankaranarayanan S, Barten DM, Vana L, Devidze N, Yang L, Cadelina G et al (2015) Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models. PLoS One 10(5):e0125614
pubmed: 25933020
pmcid: 4416899
doi: 10.1371/journal.pone.0125614
Ittner A, Bertz J, Suh LS, Stevens CH, Gotz J, Ittner LM (2015) Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice. J Neurochem 132(1):135–145
pubmed: 25041093
doi: 10.1111/jnc.12821
Castillo-Carranza DL, Gerson JE, Sengupta U, Guerrero-Muñoz MJ, Lasagna-Reeves CA, Kayed R (2014) Specific targeting of tau oligomers in htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds. J Alzheimers Dis 40(s1):S97–S111
pubmed: 24603946
doi: 10.3233/JAD-132477
Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Kiritoshi T, Neugebauer V et al (2012) Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci Rep 2:700
pubmed: 23050084
pmcid: 3463004
doi: 10.1038/srep00700
Igawa T, Tsunoda H, Kuramochi T, Sampei Z, Ishii S, Hattori K (2011) Engineering the variable region of therapeutic IgG antibodies. MAbs 3(3):243–252
pubmed: 21406966
pmcid: 3149705
doi: 10.4161/mabs.3.3.15234
Xu H, Rosler TW, Carlsson T, de Andrade A, Fiala O, Hollerhage M et al (2014) Tau silencing by siRNA in the P301S mouse model of tauopathy. Curr Gene Ther 14(5):343–351
pubmed: 25687501
doi: 10.2174/156652321405140926160602
Sud R, Geller ET, Schellenberg GD (2014) Antisense-mediated exon skipping decreases tau protein expression: a potential therapy for tauopathies. Mol Ther Nucleic Acids 3:e180
pubmed: 25072694
pmcid: 4121519
doi: 10.1038/mtna.2014.30
Schoch KM, DeVos SL, Miller RL, Chun SJ, Norrbom M, Wozniak DF et al (2016) Increased 4R-tau induces pathological changes in a human-tau mouse model. Neuron 90(5):941–947
pubmed: 27210553
pmcid: 5040069
doi: 10.1016/j.neuron.2016.04.042